<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A subset of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> shows significant accumulation of aberrant promoter methylation </plain></SENT>
<SENT sid="1" pm="."><plain>Previously, we developed two groups of methylation markers that classified <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> into three epigenotypes: i) high-, ii) intermediate-, and iii) low-methylation epigenotypes </plain></SENT>
<SENT sid="2" pm="."><plain>High-methylation epigenotype, with methylation of both group 1 and group 2 markers, correlates to BRAF-mutation((+)) </plain></SENT>
<SENT sid="3" pm="."><plain>Intermediate-methylation epigenotype, with methylation of group 2 markers, but not group 1, correlates to KRAS-mutation((+)) </plain></SENT>
<SENT sid="4" pm="."><plain>To gain insight into epigenotype development in colorectal <z:e sem="disease" ids="C0596263" disease_type="Neoplastic Process" abbrv="">carcinogenesis</z:e>, especially intermediate-methylation epigenotype and its correlation to KRAS-mutation((+)) in <z:mpath ids='MPATH_270'>adenoma</z:mpath>, we analyzed methylation levels of group 1 and group 2 markers quantitatively by matrix assisted laser desorption ionization-time of flight mass spectrometry, in 51 <z:mpath ids='MPATH_270'>adenomas</z:mpath>, 13 <z:mpath ids='MPATH_557'>aberrant crypt foci</z:mpath>, and 26 <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa samples, and we compared them to 149 previously analyzed <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> samples </plain></SENT>
<SENT sid="5" pm="."><plain>Three serrated <z:mpath ids='MPATH_270'>adenomas</z:mpath> were <z:hpo ids='HP_0000001'>all</z:hpo> BRAF-mutation((+)), showing great methylation of group 1 and group 2 markers, thus high-methylation epigenotype </plain></SENT>
<SENT sid="6" pm="."><plain>Forty-eight conventional <z:mpath ids='MPATH_270'>adenomas</z:mpath> were not methylated in group 1 markers and were classified into two clusters with higher and lower methylation of group 2 markers, thus into intermediate- and low-methylation epigenotypes, respectively </plain></SENT>
<SENT sid="7" pm="."><plain><z:mpath ids='MPATH_270'>Adenoma</z:mpath> with intermediate-methylation epigenotype correlated to KRAS-mutation((+)) </plain></SENT>
<SENT sid="8" pm="."><plain>Methylation levels of group 2 markers in <z:mpath ids='MPATH_270'>adenoma</z:mpath> were higher than <z:mpath ids='MPATH_557'>aberrant crypt foci</z:mpath> and <z:mpath ids='MPATH_458'>normal</z:mpath> samples, but similar to <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>These data suggested that epigenotype development occur at an earlier stage than <z:mp ids='MP_0002038'>carcinoma</z:mp> formation, and already be completed at the <z:mpath ids='MPATH_270'>adenoma</z:mpath> stage </plain></SENT>
<SENT sid="10" pm="."><plain>Intermediate methylation epigenotype and its correlation to KRAS-mutation((+)) were developed in conventional <z:mpath ids='MPATH_270'>adenoma</z:mpath> </plain></SENT>
</text></document>